Stockscreener 앱 받기
59.24
2.87%
-1.75
전일 마감가:
$60.99
열려 있는:
$61.08
하루 거래량:
787.55K
Relative Volume:
0.72
시가총액:
$4.94B
수익:
$1.73B
순이익/손실:
$682.64M
주가수익비율:
7.6573
EPS:
7.7364
순현금흐름:
$411.18M
1주 성능:
-8.44%
1개월 성능:
-12.35%
6개월 성능:
-17.38%
1년 성능:
-11.34%
1일 변동 폭
$58.98
$61.73
1주일 범위
$58.80
$65.03
52주 변동 폭
$58.80
$90.87
PTC 테라퓨틱스 Stock (PTCT) Company Profile
명칭
Ptc Therapeutics Inc
전화
(908) 222-7000
주소
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Compare PTCT vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
59.24 | 4.94B | 1.73B | 682.64M | 411.18M | 7.7364 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
PTC 테라퓨틱스 Stock (PTCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-14 | 재개 | Leerink Partners | Outperform |
| 2026-06-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2026-05-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2026-05-08 | 업그레이드 | TD Cowen | Hold → Buy |
| 2026-04-10 | 개시 | Raymond James | Outperform |
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2025-12-01 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-06-17 | 개시 | Truist | Buy |
| 2025-05-09 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-05-07 | 업그레이드 | Citigroup | Sell → Neutral |
| 2025-03-11 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2025-03-07 | 개시 | Scotiabank | Sector Perform |
| 2024-12-13 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-09-04 | 개시 | Robert W. Baird | Outperform |
| 2024-08-26 | 재개 | UBS | Buy |
| 2024-05-20 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-10-30 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-10-27 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2023-10-06 | 다운그레이드 | Truist | Buy → Hold |
| 2023-09-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-09-15 | 다운그레이드 | Raymond James | Outperform → Underperform |
| 2023-03-17 | 개시 | SVB Securities | Market Perform |
| 2022-12-14 | 개시 | Goldman | Sell |
| 2022-09-12 | 개시 | Jefferies | Buy |
| 2022-09-09 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2022-04-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-10-18 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-03-29 | 업그레이드 | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-01-05 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-11-30 | 다운그레이드 | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-10-07 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-04-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-02-20 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-02-20 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-05-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | 개시 | Bernstein | Outperform |
| 2018-10-03 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-07-19 | 개시 | Credit Suisse | Outperform |
| 2018-06-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-29 | 재개 | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2017-10-26 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
모두보기
PTC 테라퓨틱스 주식(PTCT)의 최신 뉴스
Form 4 PTC Therapeutics Inc: Mark Elliott Boulding (EXEC. VP AND CLO) For: 9 October - Investing.com Canada
PTC Therapeutics CLO Mark Boulding sells $12,337 in stock - Investing.com
PTC Therapeutics (NASDAQ:PTCT) VP Mark Elliott Boulding Sells 192 Shares of Company Stock - MarketBeat
After exercising options at $39.42, PTC Therapeutics (PTCT) CLO Boulding sells 192 shares. - Stock Titan
PTC Therapeutics (NASDAQ:PTCT) Reaches New 12-Month LowTime to Sell? - MarketBeat
Ptc Therapeutics stock hits 52-week low at $61.20 - Investing.com
PTC Therapeutics, Inc. (PTCT) Stock Forecasts - Yahoo Finance
Form 4 PTC Therapeutics Inc: Glenn JR MD Phd Steele (Director) For: 30 September - Investing.com Nigeria
PTC Therapeutics, Inc. (PTCT) Stock Forecasts - Yahoo Finance
PTC Therapeutics, Inc. (NASDAQ:PTCT) Stock Has Consensus Target Price of $98.25 According to Brokerages - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Stock Gets Downgrade from Wall Street Zen - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Director Sells 2,500 Shares of Company Stock - MarketBeat
Under a trading plan, Section Six sells 2,500 PTC Therapeutics (PTCT) shares. - Stock Titan
Officer Mark Elliott Boulding proposes selling 192 shares of PTC Therapeutics (Nasdaq: PTCT). - Stock Titan
PTC Therapeutics insider sold 1,638 shares while PTC Therapeutics stock fell 1.36 percent - AD HOC NEWS
PTC Therapeutics, Inc. (PTCT) Stock Forecasts - Yahoo! Finance Canada
RBC Cuts Price Target on PTC Therapeutics to $75 From $85, Keeps Sector Perform Rating - www.marketscreener.com
PTC Therapeutics, Inc. (PTCT) Stock Forecasts - Yahoo Finance
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) VP Sells $27,909.60 in Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Stock: Insider Mark Elliott Boulding Sells 1,638 Shares - MarketBeat
Form 4 PTC Therapeutics Inc For: 7 October By Investing.com - Investing.com India
PTC Therapeutics CLO Mark Boulding sells $132,790 in shares - Investing.com
Form 4 PTC Therapeutics Inc For: 7 October By Investing.com - Investing.com UK
Under a trading plan, PTC Therapeutics (PTCT) CLO sells 1,638 shares, then 435 more. - Stock Titan
Director-linked partnership proposes selling 10,000 PTC Therapeutics (PTCT) shares. - Stock Titan
PTC Therapeutics Retains Significant Firepower for Bolt-On Deals, RBC Capital Markets Says - marketscreener.com
RBC Capital reiterates PTC Therapeutics stock rating at Sector Perform By Investing.com - Investing.com Canada
Form 144 PTC THERAPEUTICS For: 6 October By Investing.com - Investing.com Nigeria
Cantor raises target for PTC Therapeutics stock to USD 137.00 - AD HOC NEWS
A $27.9K sale of 435 shares is proposed by PTC Therapeutics (PTCT) officer Mark Boulding. - Stock Titan
Stock Market Today, Oct. 5: Tech Momentum Lifts Nasdaq as Treasury Yields Surge - The Motley Fool
Officer Mark Boulding proposes selling 1,638 shares of PTC Therapeutics (PTCT). - stocktitan.net
PTC Therapeutics, Inc. (PTCT) Stock forecasts - uk.finance.yahoo.com
Director Steele Glenn Jr MD PHD Sells 12,000 Shares of PTC Therapeutics Inc (PTCT) - GuruFocus
PTC Therapeutics (NASDAQ:PTCT) Director Sells $781,920.00 in Stock - MarketBeat
After exercising options at $11.23, a director sold 12,000 PTC Therapeutics (PTCT) shares at $65.16. - stocktitan.net
PTCT Stock Price, Quote & Chart - ChartMill
A director proposes selling $782K in option-exercised PTC Therapeutics (PTCT) shares. - Stock Titan
Non-controlling/minority interest of PTC Therapeutics, Inc. – HAN:BH3 - TradingView
PTC Therapeutics, Inc. (PTCT) Stock Price, News, Quote & History - Yahoo! Finance Canada
PTC Therapeutics (NASDAQ:PTCT) Stock Price Up 4.7%Here's What Happened - MarketBeat
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
37 new hires get options to buy PTC shares at $65.96 - Stock Titan
Cantor raises PTC Therapeutics stock price target on Fabry deal By Investing.com - Investing.com Canada
Cantor Fitzgerald Boosts PTC Therapeutics (NASDAQ:PTCT) Price Target to $137.00 - MarketBeat
Cantor Fitzgerald maintains Overweight rating on PTC Therapeutics, $137 price target - TradingView
PTC Therapeutics completes ST-920 gene therapy acquisition By Investing.com - Investing.com Australia
PTC Completes Acquisition of ST-920, BLA Submission Expected in Q4 2026 - TradingView
PTC Completes Acquisition of ST-920 Fabry Disease Gene Therapy - marketscreener.com
A one-time gene therapy for Fabry disease is now PTC’s. FDA filing expected later in 2026. - Stock Titan
PTC 테라퓨틱스 (PTCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
PTC 테라퓨틱스 주식 (PTCT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Boulding Mark Elliott | Officer |
Oct 09 '26 |
Proposed Sale |
64.26 |
192 |
12,339 |
0 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Oct 09 '26 |
Option Exercise |
39.42 |
192 |
7,569 |
105,464 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Oct 09 '26 |
Sale |
64.26 |
192 |
12,338 |
105,272 |
| SCHMERTZLER MICHAEL | Director |
Oct 07 '26 |
Sale |
63.39 |
2,500 |
158,480 |
1,294,094 |
| Section Six Partners, L.P. | Affiliate of Director |
Oct 07 '26 |
Proposed Sale |
64.35 |
10,000 |
643,500 |
0 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Oct 06 '26 |
Sale |
64.16 |
435 |
27,910 |
105,272 |
| Boulding Mark Elliott | Officer |
Oct 06 '26 |
Proposed Sale |
64.16 |
435 |
27,908 |
0 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Oct 06 '26 |
Option Exercise |
39.42 |
435 |
17,148 |
105,707 |
| Boulding Mark Elliott | Officer |
Oct 05 '26 |
Proposed Sale |
64.03 |
1,638 |
104,883 |
0 |
| Boulding Mark Elliott | EXEC. VP AND CLO |
Oct 05 '26 |
Option Exercise |
39.42 |
1,638 |
64,570 |
106,910 |
1.82%
0.03%
자본화:
|
볼륨(24시간):